Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Advanced Tumor
Lymphoma
NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Part A: OSE-279 100mg
DRUG: Part A: OSE-279 300mg
DRUG: Part A: OSE-279 600mg
DRUG: Part B: OSE-279 600 mg and OSE2101
DRUG: Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
DRUG: Part C: OSE-279 600 mg - HLA-A2 positif
DRUG: Part C: OSE-279 600 mg - HLA-A2 negative

Sponsor

OSE Immunotherapeutics